A quality-by-design approach to improve process understanding and optimise the production and quality of CAR-T cells in automated stirred-tank bioreactors

被引:3
作者
Hood, Tiffany [1 ]
Slingsby, Fern [2 ]
Sandner, Viktor [3 ]
Geis, Winfried [4 ]
Schmidberger, Timo [4 ]
Bevan, Nicola [5 ]
Vicard, Quentin [6 ]
Hengst, Julia [7 ]
Springuel, Pierre [1 ]
Dianat, Noushin [6 ]
Rafiq, Qasim A. [1 ]
机构
[1] UCL, Dept Biochem Engn, London, England
[2] Sartorius Stedim UK Ltd, Prod Excellence Bioreactor Technol, Epsom, England
[3] Sartorius Stedim Austria GmbH, Digital Solut, Vienna, Austria
[4] Sartorius Stedim Biotech GmbH, Digital Solut, Gottingen, Germany
[5] Essen BioSci Ltd, Sartorius Grp, BioAnalyt Applicat Dev, Royston, England
[6] Sartorius Stedim France SAS, Cell Culture Technol Mkt, Aubagne, France
[7] Sartorius Stedim Biotech GmbH, Cell Culture Technol Mkt, Gottingen, Germany
来源
FRONTIERS IN IMMUNOLOGY | 2024年 / 15卷
基金
英国工程与自然科学研究理事会;
关键词
immunotherapy; CAR-T; process understanding; quality-by-design; T cells; process optimisation; stirred-tank bioreactor; EXHAUSTION; ANTIGEN; CULTURE; PERSISTENCE; METABOLISM; PHENOTYPES; EXPANSION; REACTOR;
D O I
10.3389/fimmu.2024.1335932
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Ex vivo genetically-modified cellular immunotherapies, such as chimeric antigen receptor T cell (CAR-T) therapies, have generated significant clinical and commercial outcomes due to their unparalleled response rates against relapsed and refractory blood cancers. However, the development and scalable manufacture of these novel therapies remains challenging and further process understanding and optimisation is required to improve product quality and yield. In this study, we employ a quality-by-design (QbD) approach to systematically investigate the impact of critical process parameters (CPPs) during the expansion step on the critical quality attributes (CQAs) of CAR-T cells. Utilising the design of experiments (DOE) methodology, we investigated the impact of multiple CPPs, such as number of activations, culture seeding density, seed train time, and IL-2 concentration, on CAR-T CQAs including, cell yield, viability, metabolism, immunophenotype, T cell differentiation, exhaustion and CAR expression. Initial studies undertaken in G-Rex (R) 24 multi-well plates demonstrated that the combination of a single activation step and a shorter, 3-day, seed train resulted in significant CAR-T yield and quality improvements, specifically a 3-fold increase in cell yield, a 30% reduction in exhaustion marker expression and more efficient metabolism when compared to a process involving 2 activation steps and a 7-day seed train. Similar findings were observed when the CPPs identified in the G-Rex (R) multi-well plates studies were translated to a larger-scale automated, controlled stirred-tank bioreactor (Ambr (R) 250 High Throughput) process. The single activation step and reduced seed train time resulted in a similar, significant improvement in CAR-T CQAs including cell yield, quality and metabolism in the Ambr (R) 250 High Throughput bioreactor, thereby validating the findings of the small-scale studies and resulting in significant process understanding and improvements. This study provides a methodology for the systematic investigation of CAR-T CPPs and the findings demonstrate the scope and impact of enhanced process understanding for improved CAR-T production.
引用
收藏
页数:15
相关论文
共 43 条
  • [1] Addgene, 2016, Fluorescence Titering Assay for Lentivirus
  • [2] Media evaluation for production and expansion of anti-CD19 chimeric antigen receptor T cells
    Alnabhan, Rehab
    Gaballa, Ahmed
    Mork, Lisa-Mari
    Mattsson, Jonas
    Uhlin, Michael
    Magalhaes, Isabelle
    [J]. CYTOTHERAPY, 2018, 20 (07) : 941 - 951
  • [3] Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients
    Baitsch, Lukas
    Baumgaertner, Petra
    Devevre, Estelle
    Raghav, Sunil K.
    Legat, Amandine
    Barba, Leticia
    Wieckowski, Sebastien
    Bouzourene, Hanifa
    Deplancke, Bart
    Romero, Pedro
    Rufer, Nathalie
    Speiser, Daniel E.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2011, 121 (06) : 2350 - 2360
  • [4] Optimizing the production of suspension cells using the G-Rex "M" series
    Bajgain, Pradip
    Mucharla, Roopa
    Wilson, John
    Welch, Dan
    Anurathapan, Usanarat
    Liang, Bitao
    Lu, Xiaohua
    Ripple, Kyle
    Centanni, John M.
    Hall, Christine
    Hsu, David
    Couture, Larry A.
    Gupta, Shubhranshu
    Gee, Adrian P.
    Heslop, Helen E.
    Leen, Ann M.
    Rooney, Cliona M.
    Vera, Juan F.
    [J]. MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2014, 1 : 14015
  • [5] The spectrum of T cell metabolism in health and disease
    Bantug, Glenn R.
    Galluzzi, Lorenzo
    Kroemer, Guido
    Hess, Christoph
    [J]. NATURE REVIEWS IMMUNOLOGY, 2018, 18 (01) : 19 - 34
  • [6] Automated Disposable Small Scale Reactor for High Throughput Bioprocess Development: A Proof of Concept Study
    Bareither, Rachel
    Bargh, Neil
    Oakeshott, Robert
    Watts, Kathryn
    Pollard, David
    [J]. BIOTECHNOLOGY AND BIOENGINEERING, 2013, 110 (12) : 3126 - 3138
  • [7] Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
    Brentjens, Renier J.
    Riviere, Isabelle
    Park, Jae H.
    Davila, Marco L.
    Wang, Xiuyan
    Stefanski, Jolanta
    Taylor, Clare
    Yeh, Raymond
    Bartido, Shirley
    Borquez-Ojeda, Oriana
    Olszewska, Malgorzata
    Bernal, Yvette
    Pegram, Hollie
    Przybylowski, Mark
    Hollyman, Daniel
    Usachenko, Yelena
    Pirraglia, Domenick
    Hosey, James
    Santos, Elmer
    Halton, Elizabeth
    Maslak, Peter
    Scheinberg, David
    Jurcic, Joseph
    Heaney, Mark
    Heller, Glenn
    Frattini, Mark
    Sadelain, Michel
    [J]. BLOOD, 2011, 118 (18) : 4817 - 4828
  • [8] T cell metabolism drives immunity
    Buck, Michael D.
    O'Sullivan, David
    Pearce, Erika L.
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2015, 212 (09) : 1345 - 1360
  • [9] Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial
    Castella, Maria
    Caballero-Banos, Miguel
    Ortiz-Maldonado, Valentin
    Azucena Gonzalez-Navarro, Europa
    Sune, Guillermo
    Antonana-Vidosola, Asier
    Boronat, Anna
    Marzal, Berta
    Millan, Lucia
    Martin-Antonio, Beatriz
    Cid, Joan
    Lozano, Miquel
    Garcia, Enric
    Tabera, Jaime
    Trias, Esteve
    Perpina, Unai
    Canals, Josep Ma
    Baumann, Tycho
    Benitez-Ribas, Daniel
    Campo, Elias
    Yague, Jordi
    Urbano-Ispizua, Alvaro
    Rives, Susana
    Delgado, Julio
    Juan, Manel
    [J]. FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [10] Demonstrating the Manufacture of Human CAR-T Cells in an Automated Stirred-Tank Bioreactor
    Costariol, Elena
    Rotondi, Marco C.
    Amini, Arman
    Hewitt, Christopher J.
    Nienow, Alvin W.
    Heathman, Thomas R. J.
    Rafiq, Qasim A.
    [J]. BIOTECHNOLOGY JOURNAL, 2020, 15 (09)